“Asia Vaccines market set to grow to $11.7bn by 2024” says new Visiongain report

28 October 2019
Pharma

Visiongain has launched a new pharma report Asia Vaccines Market Forecast to 2029 : Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Influenza, Hepatitis, Polio, Meningococcal, DTP, Rotavirus, MMR, HPV.

Globally, Asia is identified as a lucrative market for the vaccine development companies to establish and expand their presence in economies such as Japan, China and India. In addition, introduction of new technologies for development of innovative vaccines and rising government support also drive the market during the forecast period.

The lead analyst of the report commented "The vaccines market has witnessed a strong growth in the past few years, as the demand for vaccines is increasing in many Asian countries. Increased awareness for vaccination is one of the prominent factors driving the emerging market growth. This has led to intensified vaccination programmes for adolescents and growing geriatric population.

Japan accounted for the largest share of the vaccines market in Asia. Growth in the Japanese Vaccine market is driven by two main factors. First is the easing of Japan’s strict barriers to entry for foreign companies. Secondly, growth will be further driven by the population of elderly in Japan."

Leading companies featured in the report include Astellas, AstraZeneca
CSL, Ltd., Emergent BioSolutions, Inc., GlaxoSmithKline, Johnson & Johnson, Merck, Mitsubishi Tanabe Pharma Corporation, Pfizer, Sanofi, Serum Institute of India Pvt. Ltd., Sun Pharmaceuticals Industries, Ltd., Takeda and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes RNA Analysis/Transcriptomics Market Report 2020-2030

Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.

30 November 2020

Read

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever